MicroRNA 192 Could Become a Gamechanger in Diagnosing Early-Stage Diabetic Kidney Damage
Nikhil Prasad Fact checked by:Thailand Medical News Team Apr 11, 2025 1 day, 17 hours, 35 minutes ago
Medical News: A new study by researchers from Mansoura University in Egypt has uncovered a promising new way to diagnose early-stage kidney damage caused by diabetes, long before the condition progresses into more serious and life-threatening stages. The research focused on a tiny molecule in the blood called MicroRNA-192, and findings suggest it could serve as a highly accurate early biomarker for diabetic nephropathy—a major complication of type 2 diabetes that leads to chronic kidney failure.
MicroRNA 192 Could Become a Gamechanger in Diagnosing Early-Stage Diabetic Kidney Damage
This
Medical News report explores how this new diagnostic approach could revolutionize care for millions of diabetes patients around the world. The research team conducted a case-control study comparing levels of MicroRNA-192 in the blood of diabetic patients with early kidney issues, those with more advanced kidney disease, and healthy individuals.
What Is Diabetic Nephropathy
Diabetic nephropathy (DN) is a common complication of long-term diabetes. It damages the kidneys’ filtering units, causing protein to leak into the urine and reducing their ability to clean the blood. Around 9% of people with diabetes eventually develop this condition, which can lead to end-stage renal disease (ESRD) requiring dialysis or kidney transplant. Traditionally, doctors detect DN through a test for microalbuminuria—small amounts of protein in the urine—but this method often catches the condition too late.
The Role of MicroRNA 192 in the Kidneys
MicroRNA-192 (miR-192) is a small, non-coding RNA molecule that regulates gene expression. It is mainly found in the kidney’s cortex, the outer part where filtration begins. The study found that levels of this molecule in the blood change depending on the stage of diabetic kidney damage.
In patients with early DN (Group I), MicroRNA-192 levels were significantly higher (1.35 ± 0.5) compared to both healthy individuals (Group III, 0.83 ± 0.3) and those with late-stage DN (Group II, 0.65 ± 0.2). This suggests the body produces more MicroRNA-192 early in the disease as a protective response, but levels decline as the disease worsens and kidney tissue becomes more scarred and damaged.
How the Study Was Done
The study involved 150 participants—50 in each group. Researchers took blood and urine samples, ran full biochemical tests, and used real-time polymerase chain reaction (RT-PCR) to detect and measure levels of MicroRNA-192. They also measured key kidney function markers such as creatinine, blood urea nitrogen (BUN), and estimated glomerular filtration rate (eGFR).
Importantly, MicroRNA-192 showed strong correlations with kidney function. It had a positive relationship with eGFR, meaning higher levels indicated better kidney function, and negative correlations with creatinine, urinary albumin, and albumin-to-creatinine ratios—all signs of worsening kidney function.&l
t;br />
Diagnostic Accuracy and Potential Use
Using ROC (Receiver Operating Characteristic) curve analysis, the researchers determined that MicroRNA-192 had good accuracy in diagnosing early DN. It had a sensitivity of 62% and specificity of 86% when distinguishing early DN from healthy individuals. When comparing early DN to late DN, it performed even better, with both sensitivity and specificity reaching 82%.
This means that MicroRNA-192 could not only serve as an early warning signal but may also help doctors monitor disease progression or response to treatment.
A Step Toward Better Outcomes for Diabetes Patients
The findings of this study could significantly change how diabetic kidney disease is detected and managed. By identifying at-risk individuals earlier through a simple blood test, doctors could begin interventions that slow or prevent further kidney damage. This would reduce the need for dialysis, improve quality of life, and lower healthcare costs.
While the study is still in its early stages and requires further validation in larger populations, it opens a promising new pathway in diabetes care. Future therapies might even target MicroRNA-192 directly to prevent kidney fibrosis and preserve renal function.
Conclusion
This study highlights the immense potential of MicroRNA-192 as an early and noninvasive biomarker for diabetic nephropathy. Its levels in the blood not only reflect the stage of kidney damage but also show strong correlations with standard clinical markers of kidney function. Early diagnosis is critical in chronic conditions like diabetic nephropathy, and MicroRNA-192 offers a practical and effective way to catch the disease before irreversible damage sets in. Continued research could lead to its use as both a diagnostic tool and a therapeutic target, marking a major step forward in personalized diabetes management.
The study findings were published in the peer reviewed Journal of Diabetes Research.
https://www.preprints.org/manuscript/202504.0578/v1
For the latest on Diagnostics and Kidney Issues, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/taiwanese-study-warns-that-covid-19-quietly-triggers-long-term-kidney-damage-even-without-initial-kidney-injury
https://www.thailandmedical.news/news/new-approaches-in-treating-immune-mediated-glomerular-diseases
https://www.thailandmedical.news/news/new-study-reveals-that-fasting-diet-shows-promise-for-boosting-kidney-health
https://www.thailandmedical.news/articles/nephrology-(kidneys)
https://www.thailandmedical.news/pages/thailand_doctors_listings
Follow us on:
https://x.com/ThailandMedicaX
https://www.facebook.com/ThailandMedicalNews
https://bsky.app/profile/thailandmedical.bsky.social
https://gettr.com/user/thailandmedicalnews
https://www.tribel.com/thailandmedical/wall
and 33 other social media platforms
Share
Tweet
Share
